Elena Buzzetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4532168/publications.pdf

Version: 2024-02-01

623188 433756 2,534 31 14 31 citations h-index g-index papers 33 33 33 4411 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism: Clinical and Experimental, 2016, 65, 1038-1048.	1.5	1,977
2	Gender differences in liver disease and the drug-dose gender gap. Pharmacological Research, 2017, 120, 97-108.	3.1	66
3	Collagen proportionate area is an independent predictor of longâ€term outcome in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 1214-1222.	1.9	55
4	Evaluating the association of serum ferritin and hepatic iron with disease severity in nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 1325-1334.	1.9	48
5	Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. International Journal of Endocrinology, 2015, 2015, 1-9.	0.6	41
6	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology, 2021, 75, 506-513.	1.8	40
7	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). Internal and Emergency Medicine, 2021, 16, 1005-1015.	1.0	37
8	Genetic iron overload disorders. Molecular Aspects of Medicine, 2020, 75, 100896.	2.7	28
9	Collagen proportionate area predicts clinical outcomes in patients with alcoholâ€related liver disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1728-1739.	1.9	27
10	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World Journal of Gastroenterology, 2015, 21, 11044.	1.4	25
11	Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?. European Journal of Internal Medicine, 2020, 79, 101-107.	1.0	22
12	Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. Minerva Endocrinology, 2017, 42, 184-194.	0.6	21
13	Cardiovascular morbidity and mortality is increased postâ€liver transplantation even in recipients with no preâ€existing risk factors. Liver International, 2019, 39, 1557-1565.	1.9	18
14	Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia. Internal and Emergency Medicine, 2019, 14, 423-431.	1.0	17
15	Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis. Scientific Reports, 2017, 7, 40977.	1.6	14
16	Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease). The Cochrane Library, 2017, 2017, CD011646.	1.5	13
17	Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013156.	1.5	13
18	Pharmacological interventions for acute hepatitis B infection. The Cochrane Library, 2017, 2017, CD011645.	1.5	12

#	Article	IF	CITATIONS
19	Risk of Kidney Dysfunction IN Nafld. Current Pharmaceutical Design, 2020, 26, 1045-1061.	0.9	12
20	Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements. Digestive and Liver Disease, 2019, 51, 911-913.	0.4	9
21	Establishing Reliability Criteria for Liver ElastPQ Shear Wave Elastography (ElastPQ-SWE): Comparison Between 10, 5 and 3 Measurements. Ultraschall in Der Medizin, 2021, 42, 204-213.	0.8	9
22	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013157.	1.5	7
23	Interventions for hereditary haemochromatosis. The Cochrane Library, 2017, 3, CD011647.	1.5	6
24	Iron in Porphyrias: Friend or Foe?. Diagnostics, 2022, 12, 272.	1.3	4
25	Collagen proportionate area predicts long-term mortality in patients with alcoholic hepatitis. Digestive and Liver Disease, 2022, 54, 663-668.	0.4	3
26	Comparison of pointâ€shear wave elastography (ElastPQ) and transient elastography (FibroScan) for liver fibrosis staging in patients with nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 2195-2203.	1.9	3
27	Surrogate endpoints for clinical trials in non-alcoholic steatohepatitis. The Lancet Gastroenterology and Hepatology, 2017, 2, 549-550.	3.7	2
28	Pharmacological interventions for acute hepatitis C infection. The Cochrane Library, 2018, 12, CD011644.	1.5	2
29	Pharmacological interventions for acute hepatitis C infection. The Cochrane Library, 2017, 3, CD011644.	1.5	1
30	Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes nonâ∈alcoholic fatty liver diseaseâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 339-339.	1.9	1
31	Editorial: collagen proportionate area as a prognostic indicator in NAFLD—authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1454-1455.	1.9	О